← Back to Search

TEAD Inhibitor

TEAD Inhibitor for Solid Cancers

Phase 1
Waitlist Available
Research Sponsored by Ikena Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Women who are pregnant or breastfeeding
Clinically significant cardiovascular disease as defined in the protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing IK-930, a new oral medicine, in patients with advanced solid tumors who have no other effective treatments. The medicine aims to block a protein that helps cancer cells grow.

Who is the study for?
Adults with advanced solid tumors, including mesothelioma and neurofibromatosis type 2, who have no other treatment options. Participants must be able to take oral medication and consent to tumor tissue submission. Specific groups include those with NF2 deficiency or gene fusions in the Hippo pathway.
What is being tested?
IK-930, an oral TEAD inhibitor targeting the Hippo pathway, is being tested for safety and effectiveness in two phases: Dose Escalation to find a safe dosage level followed by Dose Expansion to further assess its impact on various advanced solid tumors.
What are the potential side effects?
While specific side effects of IK-930 are not listed here as it's first-in-human use, potential risks may include typical drug reactions such as nausea, fatigue, allergic responses or more serious complications depending on how it affects the body.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I have a serious heart condition as described in the study details.
Select...
I cannot swallow or keep down oral medication.
Select...
I do not have any severe illnesses that are not under control.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
RP2D and/or MTD of IK-930
Safety and tolerability of IK-930

Side effects data

From 2023 Phase 3 trial • 29 Patients • NCT02454933
47%
Diarrhoea
41%
Paronychia
41%
Dermatitis acneiform
29%
Stomatitis
29%
Arthralgia
24%
Viral upper respiratory tract infection
24%
Cough
24%
Neutropenia
24%
Dyspnoea
24%
Pruritus
18%
Back pain
18%
Productive cough
18%
Rhinorrhoea
18%
Nausea
18%
Upper respiratory tract infection
18%
Neutrophil count decreased
18%
Dry skin
18%
Constipation
18%
Pneumonia
12%
Electrocardiogram QT prolonged
12%
Aspartate aminotransferase increased
12%
Vomiting
12%
Lung infection
12%
Musculoskeletal chest pain
12%
Alanine aminotransferase increased
12%
Decreased appetite
12%
Dizziness
12%
Dysphonia
12%
Epistaxis
12%
Rash maculo-papular
6%
Osteoporosis
6%
Colorectal cancer
6%
Tinnitus
6%
Flatulence
6%
Epigastric discomfort
6%
Hypertension
6%
Orthostatic hypotension
6%
Anaemia
6%
Spontaneous haemorrhage
6%
Ear discomfort
6%
Blepharitis
6%
Ocular hyperaemia
6%
Hypoacusis
6%
Blepharospasm
6%
Mouth ulceration
6%
Fatigue
6%
Gastritis
6%
Asthenia
6%
Catheter site injury
6%
Complication associated with device
6%
Gastroenteritis
6%
Ligament sprain
6%
Joint swelling
6%
Muscle spasms
6%
Osteoarthritis
6%
Headache
6%
Hypoaesthesia
6%
Anxiety
6%
Insomnia
6%
Renal vein embolism
6%
Urinary incontinence
6%
Milia
6%
Uterine mass
6%
Laryngeal haemorrhage
6%
Organising pneumonia
6%
Sinus congestion
6%
Onychoclasis
6%
Pain of skin
6%
Pruritus generalised
6%
Rash macular
6%
Hot flush
6%
Dry eye
6%
Eyelid pain
6%
Retinal drusen
6%
Abdominal pain
6%
Oesophageal pain
6%
Toothache
6%
Pain
6%
Seasonal allergy
6%
Atypical pneumonia
6%
Cystitis
6%
Influenza
6%
Lower respiratory tract infection
6%
Oral candidiasis
6%
Sinusitis
6%
Avulsion fracture
6%
Fall
6%
Urine analysis abnormal
6%
Bone pain
6%
Musculoskeletal pain
6%
Pain in extremity
6%
Amnesia
6%
Paraesthesia
6%
Vaginal haemorrhage
6%
Nasal congestion
6%
Pleural effusion
6%
Sneezing
6%
Eczema asteatotic
6%
Intertrigo
6%
Palmar-plantar erythrodysaesthesia syndrome
6%
Rash
6%
Skin fissures
6%
Urticaria
6%
Xanthelasma
6%
Urinary tract infection
6%
Pyrexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Osimertinib 80 mg
Osimertinib 80 mg + Durvalumab 10 mg/kg

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: IK-930 and Osimertinib Combination Dose EscalationExperimental Treatment2 Interventions
Group II: IK-930 Single Agent Dose ExpansionExperimental Treatment1 Intervention
Group III: IK-930 Single Agent Dose EscalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Osimertinib
2017
Completed Phase 4
~1100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Epithelioid Hemangioendothelioma (EHE) treatments often target specific molecular pathways involved in tumor growth and angiogenesis. TEAD inhibitors, like IK-930, focus on the Hippo pathway, which regulates cell proliferation and apoptosis. By inhibiting TEAD, these treatments aim to suppress tumor growth and induce cancer cell death. This targeted approach is significant for EHE patients as it directly interferes with the molecular mechanisms driving the disease, potentially improving treatment outcomes.
Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.Anti-angiogenic therapy for high-grade glioma.Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.

Find a Location

Who is running the clinical trial?

Ikena OncologyLead Sponsor
5 Previous Clinical Trials
441 Total Patients Enrolled
Karim Malek, MDStudy DirectorIkena Oncology
2 Previous Clinical Trials
78 Total Patients Enrolled
Sergio Santillana, MD, MScStudy ChairIkena Oncology
1 Previous Clinical Trials
150 Total Patients Enrolled

Media Library

IK-930 (TEAD Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05228015 — Phase 1
Epithelioid Hemangioendothelioma Research Study Groups: IK-930 Single Agent Dose Expansion, IK-930 and Osimertinib Combination Dose Escalation, IK-930 Single Agent Dose Escalation
Epithelioid Hemangioendothelioma Clinical Trial 2023: IK-930 Highlights & Side Effects. Trial Name: NCT05228015 — Phase 1
IK-930 (TEAD Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05228015 — Phase 1
~30 spots leftby Jun 2025